ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0711

IgA Vasculitis in a Diverse Adult Patient Population

Michelle Toker1, Urmi Khanna1, Roya Nazarian1, Adhya Mehta2, Bibi Ayesha1, Anand Kumthekar1 and Benedict Wu1, 1Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 2Jacobi Medical Center, Bronx, NY

Meeting: ACR Convergence 2023

Keywords: classification criteria, Cohort Study, race/ethnicity, Vasculitis, Vasculitis, Cutaneous

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Immunoglobulin-A (IgA) Vasculitis (IgAV) is a small-vessel vasculitis that is primarily diagnosed based on the European League Against Rheumatism (EULAR) criteria. There is limited knowledge about the IgAV phenotype in a racially and ethnically diverse population. We aimed to describe the clinicopathologic characteristics of IgAV in our adult skin of color (SOC) patients.

Methods: We retrospectively reviewed adult patients ( >18 years) from the dermatopathology database with leukocytoclastic vasculitis (LCV) at Montefiore Medical Center between January 2012–December 2022 (Figure 1). We collected demographic, clinical, laboratory, and histopathological data from the electronic medical record to identify individuals with SOC who met EULAR criteria. We defined SOC as any non-White race/ethnicity. Descriptive statistics and Fisher’s exact test were used to analyze the SOC cohort.

Results: We identified 65 patients with LCV, 52 patients met EULAR criteria for IgAV, of which 42 (81%) were SOC. In our SOC cohort of 42 patients, 32 (76%) identified themselves as Spanish/Hispanic/Latino, 7 (17%) identified themselves as Black, and 3 (7%) identified themselves as Asian. The mean (±SD) age was 56 (±16) years and 29 (69%) were females. The median (IQR) number of affected body sites was 3 (2-5). Renal involvement was present in 36 (86%) patients (Table 1). Gastrointestinal (GI) involvement was present in 16 (38%) and joint involvement was present in 5 (12%). Elevated neutrophil/lymphocyte ratio (NLR) was present in 22 (52%). Elevated serum IgA levels were present in 13 (62%) of the 21 patients with measured serum IgA. Skin biopsy direct immunofluorescence (DIF) was performed in 28 (67%) patients and showed IgA and C3 in 11 (39%) and 19 (64%), respectively. Remission was achieved in 34 (81%) patients and 8 (19%) experienced relapse.

We further analyzed the 28 patients who had skin biopsy with DIF and compared those with and without IgA deposition (Figure 1). The IgA+ group had significantly lower prevalence of renal involvement (p=0.0161), higher prevalence of GI involvement (p=0.0204), high NLR (p=0.0238), and C3 deposition on DIF (p=0.0039), and greater number of affected body sites (p=0.0206). Lesions above waistline and elevated serum IgA were not associated with systemic symptoms, including renal involvement, or positive DIF. Elevated NLR was associated with IgA deposition (p=0.0209).

Conclusion: In contrast to previous studies, the majority of our adult SOC patients had renal or GI involvement with IgA+ DIF being associated with lower prevalence of renal involvement. Additionally, our SOC patients with IgA+ DIF had more widely distributed lesions. Cutaneous involvement above the waist was not associated with renal complications. Prior studies showing the predictive value of skin biopsy and lesion location in predominantly White populations may not apply to SOC patients.

Supporting image 1

Figure 1: Study population subdivided by IgA on direct immunofluorescence (DIF)

Supporting image 2

Table 1: Disease characteristics of IgA vasculitis


Disclosures: M. Toker: None; U. Khanna: None; R. Nazarian: None; A. Mehta: None; B. Ayesha: None; A. Kumthekar: None; B. Wu: None.

To cite this abstract in AMA style:

Toker M, Khanna U, Nazarian R, Mehta A, Ayesha B, Kumthekar A, Wu B. IgA Vasculitis in a Diverse Adult Patient Population [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/iga-vasculitis-in-a-diverse-adult-patient-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/iga-vasculitis-in-a-diverse-adult-patient-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology